The Foundayo launch has marked a genuinely significant moment in UK weight loss treatment. Foundayo (orforglipron) received MHRA authorisation on 10 August 2026 for both weight management and type 2 diabetes. It is the first GLP-1 weight loss pill with no food or water restrictions to be licensed in this country. Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist developed by Eli Lilly and Company. It belongs to the same therapeutic family as Wegovy (semaglutide) and Mounjaro (tirzepatide) but delivered as a daily tablet rather than a weekly injection. What sets it apart from every other oral GLP-1 option currently available is its complete freedom from food and water restrictions at the time of administration, a flexibility made possible by its small-molecule design rather than the peptide-based chemistry of existing GLP-1 medications. While Foundayo is now MHRA-authorised, commercial availability through UK prescribers and pharmacies is developing progressively, and patients should speak to a registered clinician or pharmacy for the most current access information. At J E Williamson Pharmacy in Bishops Stortford, we are closely monitoring the rollout of Foundayo and are here to help every patient understand whether it could be the right treatment for their individual circumstances, alongside currently available options including Mounjaro and Wegovy.
Foundayo is now MHRA-authorised, and the clinical team at J E Williamson Pharmacy in Bishops Stortford is ready to discuss whether it or an existing licensed treatment such as Mounjaro or Wegovy is the right choice for your individual weight loss goals. Book now and begin your weight loss journey with the fully informed, personalised treatment decision that your health and your goals deserve.
Key takeaways
- Foundayo (orforglipron) was authorised by the MHRA on 10 August 2026 for weight management and type 2 diabetes, making it the first GLP-1 weight loss pill with no food or water restrictions to be licensed in the UK.
- Commercial availability through UK prescribers and pharmacies is developing progressively following MHRA authorisation. Patients should access Foundayo only through appropriately regulated UK prescribing and pharmacy services.
- Unlike the Wegovy pill, which must be taken on an empty stomach thirty minutes before food, Foundayo can be taken at any time of day with or without food or drink, due to its small-molecule design.
- Clinical trial data from the ATTAIN programme shows average weight loss of around 11 to 12% of body weight over 72 weeks, which is clinically meaningful but lower than Mounjaro at approximately 20 to 22% and injectable Wegovy at approximately 15%.
- Foundayo is not recommended for patients with a personal or family history of medullary thyroid carcinoma or MEN2, based on findings in animal studies, and is not suitable for use during pregnancy or breastfeeding.
- Patients who are needle-averse or who find the administration requirements of the Wegovy pill difficult to maintain may find Foundayo’s once-daily flexible dosing particularly well-suited to their circumstances.
The Importance of the Foundayo Launch
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist developed by Eli Lilly and Company. It works by activating GLP-1 receptors in the brain and gut to reduce appetite, slow gastric emptying, and improve blood sugar regulation; the same fundamental mechanism as Wegovy and Mounjaro. What makes Foundayo genuinely different from every other GLP-1 weight loss treatment currently available is the combination of its oral delivery format and its complete freedom from food and water restrictions at the time of administration. The Wegovy pill, which received MHRA approval in the UK in June 2026 as a newly approved product with availability developing progressively, also avoids the need for injections, but requires patients to take it on an empty stomach with a very small amount of water at least thirty minutes before eating or drinking anything else. Foundayo carries no such requirement and can be taken at any point in the day without regard to meals or fluid intake.
This flexibility is not a minor convenience feature. It is a clinically significant differentiator that could meaningfully improve long-term adherence for patients who find structured morning administration routines difficult to maintain. The reason Foundayo achieves this lies in its fundamental chemical structure. Most GLP-1 medications including semaglutide and tirzepatide are peptides, which are chains of amino acids that break down in the digestive system, requiring either injection or specialist absorption technology to reach the bloodstream effectively. Foundayo is a small molecule rather than a peptide, meaning it is a simpler and more stable compound that survives digestion and absorbs reliably regardless of what has been eaten or drunk. This structural difference also has manufacturing implications. Small-molecule tablets generally producible through more established and scalable processes than complex peptide medicines, which may support more reliable supply over time.
The ATTAIN Trial Programme
Foundayo’s regulatory approvals were supported by the ATTAIN phase 3 clinical trial programme, which enrolled more than 4,500 participants across multiple study arms. In ATTAIN-1, which studied adults with obesity without type 2 diabetes, participants on the highest Foundayo dose who remained on treatment lost an average of approximately 12.4% of body weight over 72 weeks, compared with 0.9% for those on placebo. In ATTAIN-2, which studied adults with obesity and type 2 diabetes, patients on the highest dose lost an average of approximately 10.5% of body weight alongside meaningful reductions in HbA1c of up to 1.8 percentage points from baseline. The ATTAIN-MAINTAIN trial examined whether patients who had already achieved weight loss using injectable GLP-1 treatments could transition to Foundayo for long-term maintenance. Early results suggest this may represent a viable strategy for some patients; a finding that is particularly relevant for those currently on Mounjaro or Wegovy who are considering their longer-term treatment plan.
The ACHIEVE-3 head-to-head trial compared Foundayo directly with oral semaglutide in adults with type 2 diabetes and found Foundayo produced greater reductions in HbA1c and slightly higher weight loss in this direct comparison, though with somewhat higher rates of gastrointestinal side effects and treatment discontinuation. These are clinical trial findings that should be interpreted in their specific population context rather than as a direct comparison with injectable Mounjaro or injectable Wegovy. The overall evidence positions Foundayo as a clinically effective weight loss option. Its efficacy sits at the lower end of the GLP-1 spectrum available in the UK but considerably above any non-GLP-1 alternative, and which is now backed by MHRA authorisation for both weight management and type 2 diabetes.
How Foundayo Compares to Existing Treatments
The table below provides a comparison of Foundayo against the GLP-1 weight loss treatments available or recently approved in the UK, based on published clinical trial data for each treatment. All figures represent the highest approved or studied doses at the relevant trial endpoint and should be considered indicative rather than directly comparable, as the trials involved different populations and designs.
| Treatment | Average weight loss | Format | Administration requirements | UK status |
|---|---|---|---|---|
| Mounjaro (tirzepatide) | Around 20 to 22% | Weekly injection | No food restrictions | MHRA-licensed; available now |
| Wegovy injection (semaglutide) | Around 15% | Weekly injection | No food restrictions | MHRA-licensed; available now |
| Wegovy pill (oral semaglutide) | Around 13 to 15% | Daily pill | Empty stomach, 30 minutes before food, small amount of water only | MHRA approved June 2026; availability developing |
| Foundayo (orforglipron) | Around 11 to 12% | Daily pill | No food or water restrictions | MHRA authorised 10 August 2026; commercial availability developing |
Whether you are interested in Foundayo or want to explore the currently available options of Mounjaro or Wegovy, the clinical team at J E Williamson Pharmacy in Bishops Stortford can help you make a fully informed, personalised treatment decision. Contact us today and benefit from the kind of personalised, clinically grounded guidance that takes the uncertainty out of one of the most important health decisions you can make.
The Foundayo Titration Schedule
Like all GLP-1 medications, Foundayo is introduced gradually through a titration schedule designed to allow the body to adjust to each dose level and minimise the severity of gastrointestinal side effects during treatment initiation. The FDA-approved US dosing schedule progresses through six steps with a minimum of thirty days at each dose level. It starts at 0.8mg once daily and progresses through 2.5mg, 5.5mg, 9mg, and 14.5mg before reaching the 17.2mg maintenance dose over approximately five months. Not all patients need to reach the highest dose, and prescribers can hold patients at a lower dose if it is producing effective results or extend the time spent at any given level if tolerability requires it. The tablet must be swallowed whole and should not be broken, crushed, or chewed. UK prescribing guidance is set out in the MHRA-approved Summary of Product Characteristics, and patients should always follow the guidance of their prescribing clinician rather than dosing information from non-UK sources.
Side Effects of Foundayo
Foundayo’s side effect profile is broadly consistent with other GLP-1 medications, with gastrointestinal effects being the most commonly reported. Nausea, diarrhoea, vomiting, constipation, abdominal bloating, indigestion, and heartburn were all reported in the ATTAIN clinical trials. These effects were most frequent during the dose escalation phase. The majority of patients experienced improvement as the body adjusted at each dose level. Headache, fatigue, and hair loss were also reported, though hair loss in the context of significant weight loss is frequently associated with the rate of weight reduction itself rather than being a specific pharmacological effect of the medication. In the ACHIEVE-3 head-to-head trial, Foundayo produced somewhat higher rates of gastrointestinal side effects and treatment discontinuation than oral semaglutide, which is a consideration for patients who are particularly sensitive to these effects.
More serious but uncommon risks include pancreatitis, gallbladder disease, and kidney problems related to severe dehydration from persistent vomiting or diarrhoea. Foundayo carries a warning regarding thyroid C-cell tumours observed in animal studies. It is not recommended for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, as the clinical relevance of these animal findings to humans has not been established. Patients with this history should discuss the risk with their prescribing clinician before starting treatment. It is not suitable for patients who are pregnant, planning a pregnancy, or breastfeeding, and should not be used alongside other GLP-1 receptor agonists. Full UK eligibility criteria and contraindications are set out in the MHRA-approved Summary of Product Characteristics, which should be consulted by prescribing clinicians before initiating treatment.
Foundayo Eligibility in the UK
Based on the ATTAIN trial eligibility criteria and the framework used for similar GLP-1 treatments in the UK, Foundayo is expected to be prescribed for adults with a BMI of 30 or above. It may also be appropriate for those with a BMI of 27 or above alongside at least one weight-related health condition such as type 2 diabetes, hypertension, or dyslipidaemia. Individual eligibility will be determined through a thorough clinical assessment with a prescribing clinician, and the approved UK prescribing criteria set out in the MHRA-authorised Summary of Product Characteristics should always be confirmed before treatment is initiated. Patients should access Foundayo only through appropriately regulated UK prescribing and pharmacy services; obtaining weight loss treatment from unregulated or unverified sources carries serious safety risks regardless of a medication’s regulatory status.
Foundayo Alongside Mounjaro and Wegovy
The arrival of Foundayo in the UK adds a meaningful new option to a weight loss treatment landscape that already includes two highly effective MHRA-licensed treatments. For patients whose priority is maximum efficacy, Mounjaro remains the most effective GLP-1 weight loss treatment available in the UK, with average weight loss figures in clinical trials that are considerably higher than those reported for Foundayo at the highest approved doses. Injectable Wegovy continues to offer a well-established, thoroughly evidenced option with years of real-world UK prescribing experience and a weight loss profile that exceeds Foundayo’s at equivalent trial timepoints. For patients whose primary barrier to treatment is needle anxiety, or who are unable to accommodate the Wegovy pill’s administration requirements in their daily routine, Foundayo now offers a genuinely new and clinically meaningful alternative that was not previously available in this country.
The ATTAIN-MAINTAIN findings also introduce an interesting possibility for patients currently on injectable GLP-1 treatments: the potential to transition to Foundayo as an oral maintenance option following initial weight loss on a more potent injectable. Patients who are thinking about their longer-term treatment plan should raise this with a prescribing clinician. The evidence base for this approach is still emerging and individual suitability will depend on a range of clinical factors. Whatever route a patient is considering, the clinical team at J E Williamson Pharmacy in Bishops Stortford is here to help them navigate the options with the clarity, confidence, and personalised guidance they deserve.
The clinical team at J E Williamson Pharmacy in Bishops Stortford is ready to help you understand the full range of MHRA-licensed weight loss options now available, including Foundayo, Mounjaro, and Wegovy, and to identify which treatment is the best fit for your individual health profile and goals. Call us to book a consultation and put the right clinical knowledge behind what could be one of the most impactful health decisions you make this year.
Frequently Asked Questions
Here are the Foundayo questions the clinical team at J E Williamson Pharmacy in Bishops Stortford is being asked most frequently by patients following the UK regulatory authorisation.
Is Foundayo available in the UK?
Foundayo (orforglipron) was authorised by the MHRA on 10 August 2026 for weight management and type 2 diabetes, meaning it is now a licensed treatment in the UK. Commercial availability through UK prescribers and pharmacies is developing progressively following authorisation, and patients should speak to a registered clinician or pharmacy for the most current access information.
How is Foundayo different from the Wegovy pill?
Foundayo is a small-molecule GLP-1 receptor agonist that can be taken at any time of day with or without food or water restrictions, whereas the Wegovy pill is a peptide-based formulation that must be taken on an empty stomach with a very small amount of water at least thirty minutes before eating or drinking anything else. Both are oral GLP-1 weight loss medications, but the fundamental difference in their chemical structures produces meaningfully different administration requirements.
Is Foundayo more effective than Mounjaro or Wegovy?
Based on the available clinical trial data, Foundayo produces average weight loss of approximately 11 to 12% of body weight, which is clinically meaningful but lower than injectable Wegovy at approximately 15% and Mounjaro at approximately 20 to 22% in their respective trials. These are separate trials with different populations rather than a direct head-to-head comparison, but the overall picture consistently positions injectable GLP-1 treatments as more effective for weight loss than oral alternatives at currently approved doses.
Where can I access Foundayo in the UK?
Foundayo is now MHRA-authorised in the UK and should be accessed only through appropriately regulated UK prescribing and pharmacy services, following a thorough clinical assessment confirming your individual suitability for the treatment. Patients should not attempt to obtain Foundayo from unregulated or unverified sources, as doing so carries serious safety risks regardless of the medication’s regulatory status.
Can I switch from Mounjaro or Wegovy to Foundayo?
Switching from an injectable GLP-1 treatment to Foundayo may be appropriate for some patients, and the ATTAIN-MAINTAIN trial explored this specifically as a long-term maintenance strategy following initial weight loss on injectable GLP-1s. Any decision to switch should be made in full consultation with a prescribing clinician who can assess your individual circumstances, treatment history, and suitability for Foundayo before any change is made.
Who might Foundayo be most suitable for?
Foundayo is likely to be particularly relevant for patients who are unwilling or unable to self-inject and who find the administration requirements of the Wegovy pill difficult to maintain consistently, as it offers a once-daily oral GLP-1 with no food or water restrictions. Based on the ATTAIN trial eligibility criteria, it is expected to be prescribed for adults with a BMI of 30 or above, or 27 or above with a weight-related health condition, though UK eligibility criteria should be confirmed against the MHRA-approved Summary of Product Characteristics.
A New Era for UK Weight Loss Treatment
The MHRA authorisation of Foundayo on 10 August 2026 represents a meaningful expansion of the weight loss treatment options available to UK patients. It brings a genuinely flexible once-daily oral GLP-1 into a landscape that already includes two highly effective injectable options and the recently approved Wegovy pill.. Whether Foundayo is the right choice for any individual patient depends on their health profile, treatment goals, lifestyle, and clinical circumstances, and those are questions best answered in a thorough consultation with a qualified healthcare professional who has access to the full MHRA-approved prescribing information. At J E Williamson Pharmacy in Bishops Stortford, our expert clinical team is committed to staying at the forefront of weight management treatment developments, helping every patient navigate their options with clarity, confidence, and the personalised clinical support they deserve. Book now and find out whether Foundayo, Mounjaro, Wegovy, or another approach is the right next step for your health and your goals.
